Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | ATM | Q13315 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7339403 | 0.98 | NPSR1 (0.55) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL70027 | 0.84 | NPSR1 (0.67) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| Hydrazine SCHEMBL27261279 | 0.79 | NPSR1 (0.56) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL28643715 | 0.79 | NPSR1 (0.56) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL5023778 | 0.79 | HDAC3 (0.58) | NPSR1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL17900427 | 0.79 | GRM6 (0.43) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL1303016 | 0.78 | NPSR1 (0.60) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL1235256 | 0.78 | LMNA (0.60) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL380126 | 0.78 | — | — | |
| SCHEMBL2265933 | 0.78 | F2 (0.41) | NPSR1LMNAPPARGNCOA2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119158536-B | Preparation method of modified silicon dioxide for adsorbing carbon dioxide | 乳山市大洋硅胶有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119502501-A | High-barrier anti-leakage packaging bag for medical instrument storage and preparation method | 江苏帕科医疗股份有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119158536-A | Preparation method of modified silicon dioxide for adsorbing carbon dioxide | 乳山市大洋硅胶有限公司 | 2024-12-20 | — | — | CN | claimed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-05-19 | — | — | US | disclosed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12415793-B2 | Modulators of TMEM16A for treating respiratory disease | TMEM16A LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| CN-119158536-B | Preparation method of modified silicon dioxide for adsorbing carbon dioxide | 乳山市大洋硅胶有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| US-6051243-A | USEFUL IN THE TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL CONDITIONS ASSOCIATED WITH A KERATINIZATION DISORDER, DERMATOLOGICAL CONDITIONS (AND THE LIKE) INCLUDING AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2000-04-18 | — | — | US | disclosed |
| EP-0912175-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0912175-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5709867-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, AND OPHTHALMOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-20 | — | — | US | disclosed |
| WO-1998000134-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5498755-A | IMINE COMPOUNDS FOR SKIN DISORDERS AND ANTIINFLAMMATORY AGENTS | ALLERGAN, INC. | 1996-03-12 | — | — | US | disclosed |
| WO-1996006070-A1 | DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-02-29 | — | — | WO | disclosed |
| US-4263205-A | FOR COLORING POLYMERS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1981-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | MDH2, MDH1, ME2 | NPSR1 4851/4885LMNA 4063/4885PPARG 993/4885 |
| US-12415793-B2 | Modulators of TMEM16A for treating respiratory disease | TMEM109, CFTR, TMEM120A | NPSR1 830/4885LMNA 2052/4885PPARG 1321/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | NPSR1 4702/4885LMNA 2920/4885PPARG 1511/4885 |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | POLQ, POLB, POLM | NPSR1 4547/4885LMNA 718/4885PPARG 2667/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | NPSR1 4616/4885LMNA 662/4885PPARG 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.